Nucleate Inside Translate Event
Join us for an engaging virtual event that explores why Australia is rapidly becoming the premier destination for clinical trials. Designed specifically for US-based founders, this 45-minute session (plus Q&A) will provide actionable insights, highlight Australia's unique advantages, and connect you with key industry leaders.
Speakers:
Michelle Gallaher – CEO of Cerulea and a seasoned expert in the Australian clinical trials landscape, offering unparalleled insights into trial execution and local opportunities.
A/Professor Lauren Ayton – Associate Dean of Innovation and Enterprise, and an expert in ophthalmological trials, medtech, and regulatory affairs.
Dr. Philip Ryan - Nucleus Network Group leader, Medical director at the Florey Institute of Neuroscience.
CSL Representative (TBC) – From Australia's largest biotech company, providing a global perspective on Australia's standing in clinical trials.
Dr. Daniel Getts (TBC) – Australian Founder and CEO of Myeloid Therapeutics. Daniel brings a wealth of first-hand experience, having established his biotech company in Boston while conducting successful clinical trials in Australia.
What to Expect:
Learn from real-world experiences of running clinical trials in Australia.
Understand the regulatory framework, tax incentives, and operational advantages.
Gain a macro-level view of how Australia compares on the global stage.
Participate in an interactive Q&A session to get your specific questions answered.
This event is a fantastic opportunity to discover how Australia can accelerate your biotech ventures and help you navigate the clinical trial process with confidence. Don’t miss the chance to connect with industry leaders and gain valuable insights to drive your success.
📅 Date: 6th of February, 9:00 AM AEST / 5th of February, 5:00 PM EST
📍 Location: Virtual Event